New drug targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage trial tests a new drug, NN3201, designed to attack cancer cells that have a specific marker called c-Kit. The study includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others. The main goal i…
Phase: PHASE1 • Sponsor: Novelty Nobility, Inc. • Aim: Disease control
Last updated May 04, 2026 16:25 UTC